The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Isoprostanes: Potential Markers of Oxidant Stress in Atherothrombotic Disease
Open accessAbstract
Abstract Isoprostanes are emerging as a new class of biologically active products of arachidonic acid metabolism of potential relevance to human vascular disease. Their formation in vivo seems to reflect primarily, if not exclusively, a nonenzymatic process of lipid peroxidation. Enhanced urinary excretion of 8-iso-PGF 2α has been described in association with cardiac reperfusion injury and with cardiovascular risk factors, including cigarette smoking, diabetes mellitus, and hypercholesterolemia. Besides providing a likely noninvasive index of lipid peroxidation in these settings, measurements of specific F 2 isoprostanes in urine may provide a sensitive biochemical end point for dose-finding studies of natural and synthetic inhibitors of lipid peroxidation. Although the biological effects of 8-iso-PGF 2α in vitro suggest that it and other isoeicosanoids may modulate the functional consequences of lipid peroxidation, evidence that this is likely in vivo remains inadequate at this time.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“F2-isoprostanes are generated from arachidonic acid through a process of nonenzymatic free radical-catalyzed lipid peroxidation, thus representing an established marker of oxidative stress.33”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Epstein, F. H., Steinberg, D. I., Parthasarathy, S., Carew, T. E., Khoo, J. C., & Witztum, J. L. (1989) · New England Journal of Medicine · doi:10.1056/nejm198904063201407 · Cited by 6,425
Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides.
Hámberg, M., Svensson, J., & Samuelsson, B. O. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.8.2994 · Cited by 3,045
Role of oxidized low density lipoprotein in atherogenesis.
Witztum, J. L., & Steinberg, D. H. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115499 · Cited by 2,675
Stephens, N. G., Parsons, A., Brown, M. J., Schofield, P. M., Kelly, F., Cheeseman, K., & Mitchinson, M. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90866-1 · Cited by 2,148
Prostaglandin Endoperoxide H Synthases (Cyclooxygenases)-1 and −2
Smith, W. L., Garavito, R. M., & DeWitt, D. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.52.33157 · Cited by 1,973
Morrow, J. D., Hill, K. E., Burk, R. F., Nammour, T., Badr, K. F., & Roberts, L. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.23.9383 · Cited by 1,898
Tuomilehto, J., Vidgrén, G., Toivanen, L., Tuomilehto‐Wolf, E., Kohtamäki, K., Stengård, J., Zimmet, P., Mackay, I. R., Rowley, M. J., & Koskela, P. U. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92521-6 · Cited by 1,691
The role of oxidized lipoproteins in atherogenesis
Berliner, J. A., & Heinecke, J. W. (1996) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(95)02173-6 · Cited by 1,369
Research works printed but not linked: 21
- 10.1161/atvb.16.7.831 · DOI
- 10.1161/circ.67.6.6342834 · DOI
- 10.1161/circ.80.5.2553296 · DOI
- 1986, Am J Physiol, 250, H372
- 10.1161/res.65.3.2548761 · DOI
- 10.1161/circ.86.6.1451239 · DOI
- 1997, Circulation, 96, 2492
- Reilly MP Delanty N O’Callaghan P Crean P Roy L FitzGerald GA. Increased generation of the F 2 isoprostanes IPF 2α -1 and 8-iso-PGF 2α in acute coronary angioplasty: evidence for oxidant stress during coronary reperfusion in humans. Circulation . In press.
- 1995, J Invest Med, 43, 292A
- 10.1161/str.25.2.8303731 · DOI
- 10.1161/circ.94.1.19 · DOI
- 1996, J Invest Med, 44, 223A
- Ciabattoni G Consoli A Vitacolonna E Mezzetti A Santarone S Pennese E Falco A Davi G Patrono C. In vivo formation of 8-epi-prostaglandin F 2α in diabetes mellitus: effects of tight metabolic control and vitamin E supplementation. Thromb Haemost . In press. Abstract.
- Davi G Alessandrini P Mezzetti A Minotti G Bucciarelli T Constantini F Cipallone F Bittolo Bon G Ciabattoni G Patrono C. In vivo formation of 8-epi-PGF 2α is increased in hypercholesterolemia. Arterioscler Thromb Vasc Biol . In press.
- Palinski W Witztum JL. Oxidative stress and diabetes mellitus. In: Schwartz CJ Born GVR eds. New Horizons in Diabetes Mellitus and Cardiovascular Disease . Rapid Science Publishers; 1996:81-93.
- 1992, Diabetes, 4, 61
- 10.1161/circ.87.6.8504494 · DOI
- 1994, Lancet, 344, 1383
- 1994, Nutrition, 10, 527
- 10.1161/circ.94.10.2434 · DOI
- 1995, J Biol Chem, 269, 17273
Cited by
Sorted by citations
Role of Oxidative Modifications in Atherosclerosis
Stocker, R., & Keaney, J. F. (2004) · Physiological Reviews · doi:10.1152/physrev.00047.2003 · Cited by 2,651
Oxidative stress and metabolic syndrome
Roberts, C. K., & Sindhu, K. K. (2009) · Life Sciences · doi:10.1016/j.lfs.2009.02.026 · Cited by 883
Isoprostanes: markers and mediators of oxidative stress
Montuschi, P., Barnes, P. J., & Roberts, L. J. (2004) · The FASEB Journal · doi:10.1096/fj.04-2330rev · Cited by 747
“F2-Isoprostanes promote platelet activation (70) and induce mitogenesis in vascular smooth muscle cells (61).”
BackgroundDavı̀, G., Ciabattoni, G., Consoli, A., Mezzetti, A., Falco, A., Santarone, S., Pennese, E., Vitacolonna, E., Bucciarelli, T., Costantini, F., et al. (1999) · Circulation · doi:10.1161/01.cir.99.2.224 · Cited by 742
Self-citationEndothelial function and dysfunction. Part I
Deanfield, J. E., Donald, A. E., Ferri, C., Giannattasio, C., Halcox, J., Halligan, S., Lerman, A., Mancia, G., Oliver, J. J., Pessina, A. C., et al. (2005) · Journal of Hypertension · doi:10.1097/00004872-200501000-00004 · Cited by 653
Metadata
- Authors
- Patrono, C., & FitzGerald, G. A.
- Affiliations
- University of Pennsylvania (US)
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 1997-11
- Volume
- 17
- Issue
- 11
- Pages
- 2309-2315
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2087724955
- Cited by
- 453
- References
- 61
- Citations by year
- 2026: 1 · 2025: 3 · 2023: 4 · 2022: 5 · 2021: 2 · 2020: 4 · 2019: 6 · 2018: 3 · 2017: 6 · 2016: 9 · 2015: 11 · 2014: 8 · 2013: 10 · 2012: 15
- FWCI
- 20.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Arteriosclerosis Thrombosis and Vascular Biology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bayer
- Wellcome Trust
- European Commission
- National Institutes of Health
- National Heart, Lung, and Blood Institute (P50HL054500, 1P50HL54500)
- National Center for Research Resources (MO1-RR-00040, M01RR000040)
- Topics
- Health Sciences › Medicine › Biochemistry (medical) › Antioxidant Activity and Oxidative Stress
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Keywords
- isoprostanes, lipid peroxidation, oxidative stress, arachidonic acid metabolism, atherothrombosis, urinary biomarkers, cardiovascular risk factors, smoking, diabetes mellitus, hypercholesterolemia, ischemia-reperfusion injury, lipid peroxidation inhibitors, dose-finding
- MeSH terms
- Antioxidants, Arteriosclerosis, Cardiovascular Diseases, Diabetes Mellitus, Free Radicals, Humans, Hyperlipidemias, Immunoassay, Indicator Dilution Techniques, Gas Chromatography-Mass Spectrometry, Platelet Aggregation, Prostaglandins F, Risk Factors, Thrombosis, Vasoconstrictor Agents, Lipid Peroxidation, Dinoprost, Biomarkers, Oxidative Stress, F2-Isoprostanes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
